Post-earnings recap
Reported
Tue, Aug 11, 2026
EPS actual
$-0.37
EPS est.
$-0.31
EPS surprise
-18.21%
1-day move
-4.81%
Tango Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.81% decline in its stock price. The company did not provide any revenue figures, leading to uncertainty among investors. The lack of management commentary further adds to the cautious sentiment surrounding the stock.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | $-0.32 | -18.21% |
| Revenue | $0M | $0M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $4 billion, it operates in the health care sector, addressing significant medical needs through its research and development efforts.
Last quarter
In Q1-2026, Tango reported an EPS of $-0.32, matching analyst expectations with a slight surprise. The stock reacted positively, gaining 8.55% the following day.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
+111.81%
Avg 1-day reaction
+1.99%
Analysts expect Tango to report a loss of $-0.32 per share, with no revenue anticipated. The market will be looking for any signs of progress in their drug development pipeline.
Bull case
If Tango can demonstrate advancements in its therapies or provide positive updates on clinical trials, it could lead to a significant stock price increase.
Bear case
Conversely, if the company fails to provide any positive news or shows delays in its development pipeline, it could result in a negative market reaction.
Key metrics to watch
EPS
$-0.32Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$0MAlthough no revenue is expected this quarter, any updates on future revenue potential will be closely watched.
The print will turn on these.
Q1
What updates can management provide on the progress of their drug development pipeline?
Investors will be keen to understand any advancements or setbacks, as this could significantly impact future revenue potential.
Q2
Will the company provide any guidance on expected timelines for upcoming clinical trials?
Timelines for clinical trials can influence investor sentiment and expectations for future earnings.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for positive updates on drug development, which could lead to a more favorable outlook than currently anticipated.
Supporting evidence
Tango has a history of surprising analysts with better-than-expected results, as seen in previous quarters.
The options market is pricing in a lower move than the historical average, suggesting potential for a larger reaction.
The recent positive trend in stock reactions following earnings could indicate a shift in investor sentiment.
Key risk
If the company provides a clear timeline for clinical trials that exceeds expectations, it could significantly alter the current consensus.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to advance its therapies and provide clear guidance.
Bull confirmed if
Positive updates on drug development progress and timelines could lead to a bullish sentiment.
Bear confirmed if
Any delays or negative news regarding the drug pipeline could confirm the bear case.
What the market is pricing for the move.
Implied Move
±8.57%
Historical Avg
±14.2%
The options market is pricing in an 8.57% move, suggesting that traders expect some volatility around the earnings announcement.
Options are pricing ±8.6% while TNGX has averaged ±14.2% over the last 8 prints — setup is pricing cheap.
ATM IV
1.1%
30d HV
93.8%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$660,796.08
27,000 sh
1 insider
Net
$660,796.08
Net selling
Most Active Insiders· 2 open-market trades
$660,796.08
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
128.50%
of float
Insider
1.19%
of float
Holders
338
institutions
Top Holders· as of Jun 2026
RTW Investments LP
13,900,620 sh · $303.5M
8.24%
4.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Tango beats expectations, history suggests a potential stock increase of around 0.09%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical averages suggesting a drop of around 5.68%.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $24.45
26,400 sh
$645,604.08
Oct 1, 2026 · @ $25.32
600 sh
$15,192.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
12,438,444 sh · $271.5M
7.38%
42.2%
FMR, LLC
12,333,339 sh · $269.2M
7.31%
24.5%
Farallon Capital Management LLC
12,277,000 sh · $268.0M
7.28%
34.9%
Boxer Capital Management, LLC
10,876,219 sh · $237.4M
6.45%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.